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Abstract 
Periostin is an extracellular matrix protein, and in bone is expressed most highly in the 
periosteum. It increases bone formation through osteoblast differentiation, cell adhesion, Wnt 
signalling and collagen cross-linking. 
We hypothesised that serum periostin would be high at times of life when cortical modeling 
is active, in early adulthood and in older age, and that it would correlate with cortical bone 
measures, bone turnover and hormones that regulate cortical modeling. 
We conducted a cross-sectional observational study of 166 healthy men and women at three 
skeletal stages; the end of longitudinal growth (16-18 years), peak bone mass (30-32 years) 
and older age (over 70 years). We measured serum periostin with a new ELISA optimised for 
human serum and plasma which recognises all known splice variants (Biomedica). We 
measured the distal radius and distal tibia with HR-pQCT, and measured serum PINP, CTX, 
sclerostin, PTH, IGF-1, estradiol and testosterone.  
Periostin was higher at age 16-18 than age 30-32 (1253 vs 842 pmol/l, p<0.001), but not 
different between age 30-32 and over age 70. Periostin was inversely correlated with tibia 
cortical thickness and density (R -0.229, -0.233, both p=0.003). It was positively correlated 
with PINP (R 0.529, p<0.001), CTX (R 0.427, p<0.001) and IGF-1 (R 0.440, p<0.001). 
When assessed within each age group the correlations were only significant at age 16-18, 
except for PINP which was also significant over age 70. 
We conclude that periostin may have a role in IGF-1 driven cortical modeling and 
consolidation in young adults, but it may not be an important mediator in older adults.  
 
Key words: HR-pQCT, cortex, peak bone mass, aging, bone turnover, periostin 
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1 Introduction 
1.1 Bone size, geometry, density and microarchitecture are important determinants of bone 
strength. Understanding the regulation of these properties during skeletal maturation and 
aging is important in developing therapeutic strategies to prevent osteoporosis and fragility 
fractures. 
Periostin is an extracellular matrix protein expressed in bone, cartilage, ligaments, lung and 
other sites. It was first described in 1993 and initially named osteoblastic-specific factor 2 [1]. 
There are seven alternative splice variants in the C-terminal domain, leading to seven 
different isoforms [2, 3]. It is involved in heart valve development, wound healing, fibrotic 
processes and cancer invasion [4-6]. In bone, it is produced mainly by osteoblasts and 
osteocytes. It is expressed most highly in the periosteum [7] and in vitro and animal studies 
suggest that it enables bone formation through several mechanisms. It increases osteoblast 
differentiation and proliferation [7]DQGLQKLELWVGHJUDGDWLRQRIȕcatenin, partly through 
inhibition of sclerostin Wnt signalling [8]. It enables cell adhesion and mobility by acting as a 
ligand for integrins [7]. It increases collagen cross-linking through activation of lysyl oxidase 
[9]. Periostin knock-out mice have low bone mass, reduced cortical bone volume and 
increased intracortical modeling with aging [8, 10]. Periostin may be particularly important in 
the bone formation response to mechanical loading and intermittent PTH [11]. 
 
Genetic variability in periostin contributes to the heritability of bone microstructure at the 
radius and tibia; it is positively correlated with BV/TV and cortical thickness, and inversely 
correlated with cortical porosity [12]. However, periostin (using different assays) is not 
strongly correlated with BMD by DXA [12-15] and periostin alleles do not associate with 
DXA BMD in genome-wide analysis [16]. Serum periostin was positively correlated with 
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femoral neck cortical thickness by QCT in older men and women, but not after adjustment for 
age and gender [12].  
Higher serum periostin has been associated with higher fracture risk in postmenopausal 
women, and the association with non-vertebral fracture seems to be stronger than with 
vertebral fracture (13, 14). 
 
1.2 We have previously shown that there is cortical consolidation beyond the end of 
longitudinal growth to peak bone mass [17]. With aging there is an increase in cortical 
perimeter which is thought to be an adaptive response to maintain bone strength when bone 
mass decreases [18].  
Therefore, circulating periostin might be high in young adults when there is active cortical 
modeling, and in older adults when periosteal circumference increases. Testosterone and 
IGF-1 are thought to increase periosteal apposition, particularly during growth and 
consolidation, and it is possible that their action is mediated through periostin. 
 
Some of the indeterminate results of previous human clinical studies of periostin may be due 
to the different assays in use. Some of the previously reported assays were not optimised for 
use in human serum, and not all were well characterised for which splice variants they 
detected.  A recently released ELISA (June 2016, Biomedica Gruppe, Vienna, Austria) for 
periostin may be an improvement on previous assays for clinical human studies. This new 
assay recognises all seven known splice variants of human periostin and the calibrators and 
controls are produced in a human serum matrix [19]. 
 
1.3 The aims of this study were 1) To describe how serum periostin measured by the 
Biomedica assay varies by gender and age, 2) To determine if serum periostin is associated 
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with radius and tibia HR-pQCT cortical bone measures at end of growth, peak bone mass and 
older age, 3) To determine if serum periostin is associated with biochemical markers of bone 
turnover and hormones at end of growth, peak bone mass and older age. 
 
2 Methods 
We conducted a single-centre, cross-sectional, observational study.  
2.1 Subjects 
We recruited 180 healthy volunteers through poster advertisements, emails to hospital and 
university staff and mailing from Sheffield general practices. We studied 30 men and 30 
women in each of three age groups; 16-18 years to represent the end of longitudinal growth 
30-32 years to represent peak bone mass and over 70 years to represent aging. Volunteers 
were excluded if they had any disease or were taking any medication known to affect bone 
metabolism (such as inflammatory disease or cancer; hormonal contraceptives other than 
Depo-Provera were allowed), if they did not have at least two evaluable vertebrae on dual-
energy x-ray absorptiometry (DXA), had previously fractured both radii or tibiae, if there 
were any other conditions that would affect the reliability of the study measurements, if they 
were pregnant or trying to conceive or if they were unable to give informed consent. We 
screened 268 volunteers to recruit 180 participants who. Fourteen participants were excluded 
from this analysis due to significantly abnormal biochemical results (vitamin D deficiency, 
high PTH or high PINP) or insufficient volume of serum sample to make all the 
measurements. There was one missing result for serum testosterone, otherwise data were 
complete for all 166 participants included in this analysis. The study was approved by the 
Sheffield Research Ethics Committee, conducted according the Declaration of Helsinki, and 
all participants gave written informed consent. 
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2.2 Imaging 
Bone density at the lumbar spine and hip in g/cm2 was measured by DXA (Hologic 
Discovery, Bedford, MA, USA). HR-pQCT images of the distal radius and distal tibia were 
obtained with the XtremeCT device (Scanco Medical AG, Zurich, Switzerland) using 
standard protocols. In subjects aged 16-18 who had visible growth plates on the scout image, 
the image stack was obtained from 1mm proximal to the proximal limit of the growth plate 
[20]. HR-pQCT images were analysed with standard software provided by Scanco Medical 
AG (version 6). 
 
2.3 Biochemistry 
Blood samples were all taken in the morning, after an overnight fast. 
Serum PINP (CV 2.1%), CTX (CV 6.8%), PTH (CV 5.0%), estradiol (CV 3.9%) and 
testosterone (CV 2.2%) were measured with the Cobas e411 analyser (Roche Diagnostics,  
Pensberg, Germany). In participants with serum estradiol below the lower limit of detection 
(<5 pg/ml), a value of 4 pg/ml was assigned for analysis (this was done for 12 women over 
age 70). IGF-1 was measured using a manual ELISA (ImmunoDiagnostic Systems, Boldon, 
UK) (CV 5.7%). Serum sclerostin and periostin were measured with quantitative sandwich 
ELISA kits from Biomedica (Vienna, Austria). The intra-assay and inter-assay CVs DUH
DQGUHVSHFWLYHO\7KHSHULRVWLQ(/,6$DVVD\XVHVDPRXVHPRQRFORQDODQWLERG\
directed against the mid-region and a goat polyclonal antibody directed against epitopes that 
spread across the whole periostin molecule and that are mostly conserved between the 
isoforms. The range for the assay is 125 to 4000 pmol/L. 
 
2.4 Statistics 
7 
 
The original study included duplicate measurements to study the short term reproducibility of 
the HR-pQCT and method comparison with standard pQCT, so sample size was determined 
according to the ISCD in accordance with recommendations for estimating the 
reproducibility of repeat measurements[21]. 
Statistical analysis was done with SPSS version 22.0. 
General linear model (GLM) univariate analysis with Tukey post-hoc comparison was used 
to compare groups by age and gender and assess gender-age interactions. Periostin was not 
normally distributed so was log-transformed for the GLM analysis, DQG6SHDUPDQ¶V
coefficient was used to assess correlations between periostin and other variables.  P values 
less than 0.05 were accepted as statistically significant. We did conduct multiple 
comparisons, but as this was an exploratory analysis we did not use post-hoc significance 
corrections. The reference interval for serum periostin was calculated with Medcalc, using a 
normal distribution method (when the age 16-18 group were excluded, normality tests were 
acceptable). 
 
3 Results 
3.1 Subject characteristics and spine and hip DXA BMD are shown in Table 1.  Men and 
women were shorter at age 70+ than at younger ages. In women, body mass index was higher 
with increasing age. In men and women, lumbar spine BMD was lower at age 16-18 than at 
age 30ņ32. In women, lumbar spine and total hip BMD was lower at age 70+ than at age 30-
32. 
 
3.2 Periostin  
Serum periostin did not differ between men and women. It was higher at age 16-18 than 30-
32 (p<0.001), but not different between age 30-32 and age 70+ (p=0.08) (Figure 1). There 
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was no significant gender*age interaction. Because there was no gender difference, and no 
difference between age 30-32 and age 70+, used all the participants in these age groups 
(n=108) to estimate a mature skeleton reference interval. The reference interval is 454-1323 
pmol/l. 
 
3.3 Periostin and DXA BMD 
There were no significant correlations between serum periostin and DXA BMD at the lumbar 
spine or total hip, when analysed as group and within each age group. However the 
correlation coefficients were greater in the age 16-18 group (R -0.222, p=0.093 and R -
0.0238, p=0.072) than in the other age groups (age 30-32: R 0.096, p=0.487, R -0.035, 
p=0.801 and age 70+: R 0.176 p=0.212, R 0.079 p=0.572). 
 
3.4 Radius and tibia HR-pQCT measures 
3.4.1 Cortical measures 
See Figure 2 and Figure 3. 
Radius cortical perimeter was greater in men than in women, and greater at age 70+ than at 
age 30-32. Radius cortical thickness did not differ by gender. It did not differ between age 
16-18 and age 30-32, but was lower at age 70+ than at age 30-32. Radius cortical BMD was 
higher in women than in men. It was lower at age 16-18 and age 70+ than at age 30-32.  
Tibia cortical perimeter was greater in men than women. It was higher at age 16-18 than age 
30-32 but not different at age 70+ than age 30-32. Tibia cortical thickness was higher in men 
than in women. It was lower at age 16-18 and age 70+ than age 30-32. Tibia cortical BMD 
did not differ by gender. It was lower at age 16-18 and age 70+ than at age 30-32. 
 
3.4.2 Trabecular density 
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Radius and tibia trabecular BMD was higher in men than in women (p<0.001). It was lower 
at age 70+ than at age 30-32 (radius p=0.012, tibia p=0.011), but not different at age 16-18 
than at age 30-32. 
 
3.5 Correlation of periostin with HR-pQCT measures 
Periostin was not correlated with radius or tibia trabecular BMD, any radius cortical measures 
or tibia perimeter. It was negatively correlated with tibia cortical thickness and tibia cortical 
BMD (Table 2). When analysed within each age group, these correlations were only 
significant at age 16-18. 
 
3.6 Correlation of periostin with biochemical markers of bone turnover and hormones 
Periostin was positively correlated with PINP and CTX (Table 2). When analysed within 
each age group, these correlations were both significant at age 16-18 and the correlation with 
PINP was significant at age 70+. Neither correlation was significant at age 30-32. 
Periostin was positively correlated with IGF-1 (Table 2). When analysed within each age 
group, this correlation was only significant at age 16-18. 
There were no significant correlations between periostin and PTH, estradiol, testosterone or 
sclerostin in the whole study group or any of the three age groups. When correlations with 
estradiol and testosterone were tested separately in men and women they were still non-
significant.  
 
 
4 Discussion 
4.1 This is the first study to measure circulating periostin during skeletal modeling, and 
assess the relationship with cortical measures, biochemical markers of bone turnover and 
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hormones in this young age group. It is also the first study to assess the relationship of the 
Biomedica periostin assay with age, gender, bone measures and hormones. 
We found that serum periostin is higher at age 16-18 than at age 30-32. The range of periostin 
measurements was greater at age 16-18 than other ages, which is typical for biochemical 
markers due to the higher turnover and some heterogeneity of skeletal modeling and maturity 
at this age. At age 16-18 periostin is positively correlated with IGF-1, PINP and CTX and 
inversely correlated with cortical thickness and cortical density. This suggests that periostin 
does have a role in cortical consolidation after the end of growth, and could mediate IGF-1-
driven cortical modeling. The inverse correlation with cortical density suggests that periostin 
is higher in young adults with ongoing cortical modeling, but lower in individuals who are 
nearer to peak bone mass where cortical consolidation is complete and modeling has slowed. 
There were no significant correlations between periostin and cortical measures, biochemical 
markers of bone turnover or hormones at age 30-32. This is consistent with our hypothesis 
that periostin would not have a significant biological role when there is little active cortical 
modeling. 
In older adults, cortical perimeter was greater and cortical thickness and density were lower 
than at age 30-32, but periostin was not significantly different from age 30-32. There was a 
positive correlation of periostin with PINP in older adults, but no correlation with CTX, 
cortical measures or hormones. Therefore periostin may be a more active mediator during 
cortical modeling in younger life than during the different processes of cortical aging.  
 
4.2 The only other study to report periostin by age and gender found that periostin was higher 
in men, and lower in older adults (mean age 65y) than their offspring (mean age 38y), but this 
study used a different assay [12]. Periostin was positively correlated with HR-pQCT bone 
density and architecture in older adults, but the correlations did not persist after adjustment 
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for gender, age, BMI, and years since menopause, and there were no significant correlations 
with biochemical markers of bone turnover, sclerostin, hormones or fracture. Serum periostin 
is not related to DXA BMD in older adults [12-15]. There may be a positive correlation 
between periostin and alkaline phosphatase in postmenopausal women, but no correlation 
with CTX [13], consistent with our findings of a correlation with PINP but not CTX. Serum 
periostin does not change after treatment with zoledronic acid in postmenopausal women 
with osteoporosis, again suggesting that it may not have such a significant role in age-related 
bone loss [13]. 
However, higher serum periostin has been associated with prevalent and incident fractures 
and non-vertebral fractures in postmenopausal women independently of BMD. The evidence 
for association with vertebral fracture is not as strong, which might be expected if periostin is 
more important in cortical than trabecular bone [14, 15]. It is counterintuitive to see a positive 
association between fracture risk and a factor which increases bone formation and tends to be 
positively associated with bone density. It may be that high levels of periostin in older adults 
are a response to increased strain in weaker bone. 
 
4.3 We hypothesised that periostin would be associated with cortical perimeter, but the 
significant relationships were with cortical thickness and density. Although periostin is most 
highly expressed in the periosteum, serum periostin seems to reflect activity in the whole 
cortical compartment rather than just the periosteum. 
Periostin was not correlated with estradiol or testosterone which are thought to regulate 
periosteal apposition, so sex steroids may exert their specific actions on the periosteum 
through other pathways.  
Although periostin does not seem to be strongly associated with bone measures in older 
adults, there are some situations where it could be a useful marker. Experimental evidence 
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suggests it may have an important role in the action of teriparatide on bone, and in the 
response to mechanical loading through interaction with sclerostin and Wnt signalling [22]. 
Therefore it will be of interest in studies of anabolic bone agents, and especially in studies of 
combined anabolic agents with physical stimulation.  
 
4.4 The main strength of this new periostin assay is that based on epitope mapping and the 
use of isoform measurements, all 7 known isoforms are recognised [23]. This is not the case 
for any other assay. The assays from USCN [24] and Roche Elecsys [25] did not evaluate any 
recognition of isoforms. The assay from Adipogen recognises isoforms 1 and 2, and possibly 
3 and 4 [26] and the Abbott Architect assay recognises 6 of the 7 known isoforms [27]. 
 
4.5 There are some limitations to this study. It is cross-sectional and observational, so causal 
relationships cannot be inferred. The Biomedica assay recognises all seven isoforms of 
periostin, but the tissue-specificity of the splice variants is not yet known, so it may be that an 
assay which only recognises bone isoforms would give more informative results. The 
correlations of periostin with cortical measures were stronger at the tibia than at the radius. 
This may reflect the poorer short term precision of these measurements at the radius than at 
the tibia [28]. This is partly because the cortex is very thin at the standard XtremeCT distal 
radius site. Motion artefacts are more common at the radius than at the tibia, but we repeated 
scans where necessary to get good quality images. We used the standard Scanco software for 
HR-pQCT analysis but there are more advanced methods (particularly defining the 
endocortical perimeter in older adults with endocortical resorption [29]) which might have 
given different results for the cortical thickness and density.  
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4.6 In conclusion, serum periostin is higher at the end of growth (age 16-18) than at peak 
bone mass and older age. At this age it is positively correlated with IGF-1 and biochemical 
markers of bone turnover, and negatively correlated with cortical thickness and density, 
suggesting a role in IGF-1 driven bone modeling and cortical consolidation. The relationship 
with bone turnover and cortical measures is not seen at peak bone mass (age 30-32), and 
there is a weaker correlation with PINP only in older adults (age 70+). 
Periostin may be an important mediator of cortical bone during skeletal development, but less 
important in older age. 
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Figure Legends 
 
Figure 1 Serum periostin by age and gender groups; Boxes indicate the 25th and 75th 
centiles, central lines indicate the median, whiskers indicate the minimum and maximum 
values that are not outliers, circles represent outliers.   
 
Figure 2 Radius cortical measures; Perimeter (A), thickness (B), bone mineral density (C). 
Boxes indicate the 25th and 75th centiles, central lines indicate the median, whiskers indicate 
the minimum and maximum values that are not outliers, circles represent outliers.  NS=not 
significant. 
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Figure 3 Tibia cortical measures; Perimeter (A), thickness (B), bone mineral density (C). 
Boxes indicate the 25th and 75th centiles, central lines indicate the median, whiskers indicate 
the minimum and maximum values that are not outliers, circles represent outliers.  NS=not 
significant. 
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Table 1 Group characteristics; Results given as mean (SD). 
*different to age 30-32 p<0.05 
 
Women Men 
Age group 16-18 
n=29 
30-32 
n=29 
70+ 
n=28 
16-18 
n=29 
30-32 
n=26 
70+ 
n=25 
Age, years 17.5 
(0.8) 
31.2 
(0.8) 
75.0 
(3.5) 
17.4 
(0.7) 
31.4 
(0.8) 
75.3 
(3.4) 
Height, cm 165.1 
(5.1) 
165.1 
(4.9) 
157.6* 
(5.9) 
178.9 
(7.3) 
178.7 
(6.1) 
174.8* 
(6.0) 
BMI, kg/m2 22.2* 
(3.7) 
24.3 
(4.0) 
27.4* 
(4.6) 
24.5 
(6.0) 
25.8 
(3.6) 
26.8 
(3.3) 
Lumbar spine BMD 
g/cm2 
0.965* 
(0.084) 
1.040 
(0.108) 
0.949* 
(0.167) 
0.993* 
(0.107) 
1.073 
(0.186) 
1.115 
(0.139) 
Total hip BMD 
g/cm2 
0.961 
(0.089) 
0.974 
(0.123) 
0.866* 
(0.138) 
1.077 
(0.153) 
1.074 
(0.125) 
1.021 
(0.128) 
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Table 2 Correlations E\6SHDUPDQ¶V5KR of serum periostin with cortical measures, 
biochemical markers of bone turnover and hormones, in all subjects and within each 
age group. 
 
 
All subjects Age 16-18 Age 30-32 Age 70+ 
 
R p R p R p R p 
Radius cortical perimeter -0.089 0.255 -0.098 0.464 -0.117 0.394 -0.014 0.919 
Radius cortical thickness -0.010 0.894 -0.020 0.884 0.024 0.862 0.181 0.194 
Radius cortical density -0.141 0.069 -0.075 0.578 0.185 0.177 0.090 0.522 
Tibia cortical perimeter 0.060 0.442 0.160 0.230 -0.196 0.151 -0.037 0.792 
Tibia cortical thickness -0.229 0.003 -0.368 0.004 0.043 0.757 0.051 0.715 
Tibia cortical density -0.233 0.003 -0.423 0.001 0.180 0.188 0.118 0.401 
PINP 0.529 <0.001 0.493 <0.001 -0.085 0.536 0.285 0.039 
CTX 0.427 <0.001 0.262 0.047 -0.174 0.203 0.166 0.236 
Sclerostin -0.028 0.718 0.111 0.407 0.220 0.106 0.115 0.413 
PTH -0.067 0.394 -0.040 0.764 -0.117 0.394 0.228 0.101 
IGF-1 0.440 <0.001 0.401 0.002 0.096 0.484 -0.060 0.671 
Estradiol 0.042 0.588 0.109 0.414 0.134 0.328 -0.089 0.528 
Testosterone  0.002 0.980 -0.004 0.978 -0.230 0.094 -0.051 0.717 
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